SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Peptilogics Enrolls First International Patient in Phase 2/3 Trial

The RETAIN trial of zaloganan for prosthetic joint infection has added UK trial sites.

Related stories